Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 4:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Glaucoma
Interventions: Xalatan, Travatan Z; Drug
Lead sponsor: Wills Eye; Other
Eligibility: 21 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Obesity, Metabolic Syndrome X, Hyperlipidemia, Hypertension
Interventions: Almond enriched diet, Low fat caloric diet; Behavioral
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 123 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Type 2 Diabetes, Hypertension
Interventions: Amlodipine, amlodipine / olmesartan medoxomil combination, Hydrochlorothiazide; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 21
States / cities: Los Angeles, California • Sylmar, California • Tustin, California + 18 more

Conditions: Cardiovascular Diseases, Hypertension, Cognitive Decline, Diet, Healthy
Interventions: Peanut group; Dietary Supplement
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: Hypertension
Interventions: ENACTS; Behavioral
Lead sponsor: Washington State University; Other
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hypertension, Renal Failure Chronic Requiring Hemodialysis, Blood Pressure, Dialysis
Interventions: Antihypertensive Agents, Dry weight Challenge, Extend dialysis treatment time and re-challenge estimated dry weight; Drug · Other · Dietary Supplement
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 21
States / cities: Boston, Massachusetts • Concord, Massachusetts • Jamaica Plain, Massachusetts + 9 more

Conditions: Hypertension, Cardiovascular Diseases, Vascular Diseases
Interventions: Ultrasound Renal Denervation (Paradise™ Ultrasound Renal Denervation (uRDN) System); Device
Lead sponsor: ReCor Medical, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 2
States / cities: Detroit, Michigan

Conditions: Glaucoma
Interventions: Educational - glaucoma, Dose monitoring and reminder, Educational - general, Dose monitoring; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hypertension
Interventions: Telemonitors and pharmacy management; Other
Lead sponsor: HealthPartners Institute; Other
Eligibility: 21 Years and older
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Mood Disorders, Hypertension, Diabetes, Hypercholesterolemia
Interventions: Acceptance and Commitment Therapy plus Illness Management; Behavioral
Lead sponsor: Lilian N. Dindo; Other
Eligibility: 18 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Sickle Cell Disease
Interventions: Cardiac magnetic resonance imaging (CMR); Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: GLAUCOMA 1, OPEN ANGLE, D (Disorder)
Interventions: DSLT treatment for Open-Angle Glaucoma, SLT treatment for Open-Angle Glaucoma; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Pulmonary Hypertension
Interventions: Riociguat (Adempas, BAY63-2521); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 8
States / cities: La Jolla, California • Sacramento, California • Iowa City, Iowa + 5 more

Conditions: High Blood Pressure
Interventions: Self-Help Intervention Program-High Blood Pressure; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 40 Years to 65 Years
Enrollment: 445 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Ellicott City, Maryland

Conditions: Hypertension, Pulmonary
Interventions: Selexipag, Placebo, Standard of Care (SOC): Endothelin receptor antagonist, SOC: Phosphodiesterase type 5 (PDE-5) inhibitor, SOC: Soluble guanylate cyclase stimulator; Drug
Lead sponsor: Actelion; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 13
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: PG324 Ophthalmic Solution 0.01%, PG324 Ophthalmic Solution 0.02%, Netarsudil (AR-13324) Ophthalmic Solution 0.02%, Latanoprost Ophthalmic Solution 0.005%; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 23
States / cities: Artesia, California • Inglewood, California • Newport Beach, California + 20 more

Conditions: Diabetes Mellitus, Type 2, Hypertension
Interventions: Physical Activity, Medication Adherence, Dietary Modification; Behavioral
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years to 95 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Hypertension
Interventions: Metoprolol succinate, Nebivolol, Non-invasive measurement of Cardiac Output (CO), Endothelial cell collection, Microvascular perfusion assessment using Definity; Drug · Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypertension
Interventions: Health Education, Home Blood Pressure Monitor; Behavioral · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Mankato, Minnesota

Conditions: Glaucoma
Interventions: MicroPulse TransScleral CycloPhotoCoagulation; Procedure
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 89 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Pulmonary Arterial Hypertension
Interventions: Nitric Oxide; Drug
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Refractory Hypertension
Interventions: Placebo, TC-5214; Drug
Lead sponsor: Targacept Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Heart Failure, Diastolic, Diastolic Heart Failure, Hypertension
Interventions: regadenoson; Drug
Lead sponsor: Marvin W. Kronenberg, M.D.; Other
Eligibility: 50 Years to 75 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Traumatic Brain Injury
Interventions: Mannitol, NaCl; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 1
States / cities: Indianapolis, Indiana

Search by objective public record fields.

How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?

Weight and Metabolic Effects of an Almond Enriched Hypocaloric, Low Fat Diet on Overweight and Obese Persons

18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics

Peanuts and Neurocognitive / Cardiovascular Health in Black Individuals

Engaging Native Hawaiian/Pacific Islanders and Activating Communities to Take Steps (ENACTS)

Blood Pressure in Dialysis Patients

The RADIANCE CED Study

Improve Glaucoma Medication Adherence

Home Blood Pressure Telemonitoring and Case Management to Control Hypertension

One-Day Acceptance and Commitment Training Intervention in Primary Care Patients

Novel Cardiac Magnetic Resonance Imaging to Define a Unique Restrictive Cardiomyopathy in Sickle Cell Disease

Direct vs. Conventional SLT in Open-Angle Glaucoma: A RCT

BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension

Intervention Study to Control High Blood Pressure for Korean American

A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure

Enhancing Diabetes and Hypertension Self-Management Rural Appalachian Patients In Patient-Centered Medical Homes

Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients

A Study of Cardiovascular Disparities in the Greater Mankato Somali Community to Prevent Hypertension

Laser Dosage in MicroPulse TransScleral CycloPhotocoagulation

Effect of iNO on Invasively Derived Pulmonary Pressures in Patients With PAH

TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension

Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF

Osmotic Therapy for Treatment of Intracranial Hypertension for Traumatic Brain Injury